Ignite Creation Date:
2025-12-25 @ 2:14 AM
Ignite Modification Date:
2025-12-30 @ 5:22 PM
Study NCT ID:
NCT04676360
Status:
TERMINATED
Last Update Posted:
2025-09-25
First Post:
2020-12-15
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma
Sponsor:
Jacob Soumerai, MD
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-07-01
Start Date Type:
ACTUAL
Primary Completion Date:
2023-11-27
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-11-26
Completion Date Type:
ACTUAL
First Submit Date:
2020-12-15
First Submit QC Date:
None
Study First Post Date:
2020-12-21
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-09-22
Last Update Post Date:
2025-09-25
Last Update Post Date Type:
ESTIMATED